Abstract:Background Allergic rhinitis is a common disorder that affects 10% to 40% of the population worldwide. Allergen immunotherapy (AIT) represents the only therapy that has the potential to resolve clinical symptoms of allergic rhinitis. However, up to 30% of patients do not respond to AIT. Biomarkers predicting the clinical efficacy of AIT as early as possible would significantly improve the patient selection and reduce unnecessary societal costs. Methods Artemisia pollen allergic patients who received at least 1-year AIT were enrolled. Clinical responses before and after 1-year AIT were evaluated to determine AIT responders. Artemisia specific IgE and IgG4 levels were measured by using ImmunoCAP and enzyme-linked immunosorbent assay (ELISA) separately. Stepwise regression analysis was performed to identify which rhinitis-relevant parameters explained the most variability in AIT results. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics was applied to identify the potential candidate biomarkers in the sera of responders and non-responders collected before and after 1-year therapy. The diagnostic performance of the potential biomarkers was then assessed using enzyme-linked immunosorbent assay (ELISA) in 30 responders and 15 non-responders. Results Artemisia specific IgE and IgG4 levels were elevated only in the responders. Regression analysis of allergic rhinitis-relevant parameters provided a robust model that included two most significant variables (sneeze and nasal congestion). Thirteen candidate biomarkers were identified for predicting AIT outcomes. Based on their association with allergy and protein fold change (more than 1.1 or less than 0.9), four proteins were identified to be potential biomarkers for predicting effective AIT. However, further ELISA revealed that only leukotriene A 4 hydrolase (LTA 4 H) was consistent with the proteomics data. The LTA 4 H level in responders increased significantly (P < 0.001) after 1-year therapy, while that of non-responders remained unchanged. Assessment of LTA 4 H generated area under curve (AUC) value of 0.844 (95% confidence interval: 0.727 to 0.962; P < 0.05) in distinguishing responders from the non-responders, suggesting that serum LTA 4 H might be a potential biomarker for predicting the efficiency of AIT. Conclusion Serum LTA 4 H may be a potential biomarker for early prediction of an effective AIT.

Identification of Key Genes and the Pathophysiology Associated with Allergen-Specific Immunotherapy for Allergic Rhinitis.

Identification of Key Genes in Allergic Rhinitis by Bioinformatics Analysis

Identification of Candidate Genes in Atopic Dermatitis Based on Bioinformatic Methods

Identification of diagnostic signature, molecular subtypes, and potential drugs in allergic rhinitis based on an inflammatory response gene set

Identification of gene biomarkers with expression profiles in patients with allergic rhinitis

Allergen Immunotherapy Enhances the Immunosuppressive Effects of Treg Cells to Alleviate Allergic Rhinitis by Decreasing PU-1+ Treg Cell Numbers.

Multiple-Cytokine Profiling: A Novel Method for Early Prediction of the Efficacy of Sublingual Immunotherapy in Allergic Rhinitis Patients.

Single‐cell RNA sequencing reveals the landscape of biomarker in allergic rhinitis patient undergoing intracervical lymphatic immunotherapy and related pan‐cancer analysis

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Bioinformatics analysis and identification of underlying biomarkers potentially linking allergic rhinitis and autophagy

Comprehensive Analysis Reveals Hub Genes Associated with Immune Cell Infiltration in Allergic Rhinitis

The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis

Hub Genes Identification in a Murine Model of Allergic Rhinitis Based on Bioinformatics Analysis

A Proteomics Analysis Reveals That A2M Might Be Regulated by STAT3 in Persistent Allergic Rhinitis.

[The research progress of mechanism of allergen immunotherapy in allergic rhinitis].

Changes in Immunologic Indicators During Allergen-Specific Immunotherapy for Allergic Rhinitis and Determinants of Variability: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Leukotriene A4 Hydrolase Is a Candidate Predictive Biomarker for Successful Allergen Immunotherapy

Increased Expression Of Mir-146a In Children With Allergic Rhinitis After Allergen-Specific Immunotherapy

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Mechanistic study of acupuncture on the pterygopalatine ganglion to improve allergic rhinitis: analysis of multi-target effects based on bioinformatics/network topology strategie

Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update